What is EyeControl?
EyeControl specializes in the development of sophisticated, adaptive communication tools designed to restore the voice of patients across diverse healthcare settings. By focusing on the continuum of care—from initial sedation through the recovery phase—the company provides essential technology that empowers patients to participate actively in their own medical journey. This market position is critical, as it addresses a significant unmet need for responsive, compassionate care tools that facilitate interaction between patients, medical teams, and families. Through its innovative approach, EyeControl is effectively transforming the standard of care, ensuring that patient outcomes are prioritized through enhanced connectivity and accessibility.
How much funding has EyeControl raised?
EyeControl has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2020): $10M, investors not publicly disclosed
Key Investors in EyeControl
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for EyeControl?
With this major enterprise-level funding, EyeControl is poised to accelerate its product development roadmap and broaden its market reach. The strategic allocation of this capital will likely focus on enhancing the technical capabilities of its communication platforms and expanding its presence in clinical environments globally. As the company transitions into this next phase of growth, the focus will remain on scaling its infrastructure to support a wider range of medical facilities. By leveraging this financial backing, EyeControl aims to solidify its role as an indispensable partner in the healthcare ecosystem, driving long-term value for stakeholders while fundamentally improving the patient experience.
See full EyeControl company page
